JP5081622B2 - ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法 - Google Patents

ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法 Download PDF

Info

Publication number
JP5081622B2
JP5081622B2 JP2007532749A JP2007532749A JP5081622B2 JP 5081622 B2 JP5081622 B2 JP 5081622B2 JP 2007532749 A JP2007532749 A JP 2007532749A JP 2007532749 A JP2007532749 A JP 2007532749A JP 5081622 B2 JP5081622 B2 JP 5081622B2
Authority
JP
Japan
Prior art keywords
acid
rotigotine
sustained release
pharmaceutically acceptable
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007532749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513524A (ja
JP2008513524A5 (https=
Inventor
▲張▼路平
Original Assignee
山▲東緑▼叶制▲薬▼有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 山▲東緑▼叶制▲薬▼有限公司 filed Critical 山▲東緑▼叶制▲薬▼有限公司
Publication of JP2008513524A publication Critical patent/JP2008513524A/ja
Publication of JP2008513524A5 publication Critical patent/JP2008513524A5/ja
Application granted granted Critical
Publication of JP5081622B2 publication Critical patent/JP5081622B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007532749A 2004-09-21 2005-09-21 ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法 Expired - Lifetime JP5081622B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410077961.9 2004-09-21
CN200410077961 2004-09-21
PCT/CN2005/001521 WO2006032202A1 (fr) 2004-09-21 2005-09-21 Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation

Publications (3)

Publication Number Publication Date
JP2008513524A JP2008513524A (ja) 2008-05-01
JP2008513524A5 JP2008513524A5 (https=) 2011-04-07
JP5081622B2 true JP5081622B2 (ja) 2012-11-28

Family

ID=36089849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007532749A Expired - Lifetime JP5081622B2 (ja) 2004-09-21 2005-09-21 ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法

Country Status (9)

Country Link
US (2) US8691277B2 (https=)
EP (1) EP1797871B1 (https=)
JP (1) JP5081622B2 (https=)
KR (1) KR20070059161A (https=)
AU (1) AU2005287743B2 (https=)
CA (1) CA2581143C (https=)
ES (1) ES2536460T3 (https=)
PL (1) PL1797871T3 (https=)
WO (1) WO2006032202A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
ES2402376T3 (es) * 2006-04-06 2013-05-03 Nupathe Inc. Implantes para el tratamiento de estados asociados con dopamina
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
JP2009539941A (ja) * 2006-06-16 2009-11-19 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
EP2291178A4 (en) * 2008-06-09 2013-07-24 Supernus Pharmaceuticals Inc PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE
EP2452677A1 (en) 2008-09-29 2012-05-16 Wockhardt Limited Extended release dosage form of ropinirole
FR2936710B1 (fr) * 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
AU2010266285A1 (en) * 2009-07-02 2012-02-09 Supernus Pharmaceuticals, Inc. A method of treatment of a neurological disorder
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
DE102010014113A1 (de) * 2010-04-07 2011-10-13 Acino Ag Freisetzungsverfahren für Implantate
RU2589700C2 (ru) * 2010-11-25 2016-07-10 Шан Донг Люие Фармацеутикал Ко., Лтд Композиции ротиготина, его производных, или фармацевтически приемлемых солей ротиготина или их производных
WO2012074988A1 (en) * 2010-12-02 2012-06-07 Ratiopharm Gmbh Rotigotine ionic liquid
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2018096560A1 (en) 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
US20190374534A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide
KR102212722B1 (ko) * 2019-12-23 2021-02-08 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물
WO2025243901A1 (ja) * 2024-05-21 2025-11-27 株式会社 SENTAN Pharma 注射製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
JPH10167968A (ja) * 1996-10-09 1998-06-23 Takeda Chem Ind Ltd マイクロパーティクルの製造法
CA2267930A1 (en) 1996-10-09 1998-04-16 Nobuyuki Takechi A method for producing a microparticle
ATE203157T1 (de) * 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
JP3663271B2 (ja) * 1997-01-24 2005-06-22 シュバルツ ファルマ アクチェンゲゼルシャフト 新規の分枝鎖エステル及びその製法
AU752225B2 (en) * 1998-07-17 2002-09-12 Pacira Pharmaceuticals, Inc. Biodegradable compositions for the controlled release of encapsulated substances
DK1140026T3 (da) * 1998-12-16 2006-01-02 Aventis Pharma Inc Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
GB9828861D0 (en) 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
DE60030828T2 (de) 1999-07-09 2007-02-08 Bts Holding International Bv Optische abtastvorrichtung mit umschaltbarer auflösung
CA2405205C (en) 2000-04-28 2007-11-20 Tanabe Seiyaku Co., Ltd. Method for preparing microspheres
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
WO2002087586A1 (en) * 2001-04-26 2002-11-07 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
CN1735404A (zh) * 2002-11-18 2006-02-15 波利梅里斯公司 使用新聚合物的医疗装置
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen

Also Published As

Publication number Publication date
AU2005287743A1 (en) 2006-03-30
KR20070059161A (ko) 2007-06-11
EP1797871A4 (en) 2012-11-28
CA2581143C (en) 2015-03-31
ES2536460T3 (es) 2015-05-25
HK1107012A1 (en) 2008-03-28
PL1797871T3 (pl) 2015-07-31
US20080260846A1 (en) 2008-10-23
US8691277B2 (en) 2014-04-08
US9220782B2 (en) 2015-12-29
JP2008513524A (ja) 2008-05-01
US20140255488A1 (en) 2014-09-11
EP1797871A1 (en) 2007-06-20
EP1797871B1 (en) 2015-02-25
AU2005287743B2 (en) 2011-09-29
WO2006032202A1 (fr) 2006-03-30
CA2581143A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
JP5081622B2 (ja) ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法
JP6067803B2 (ja) ロチゴチン、その誘導体、又はロチゴチン若しくはその誘導体の薬学的に許容可能な塩の組成物
RU2586306C2 (ru) Состав с микросферами для длительного непрерывного высвобождения рисперидона
CN102316867B (zh) 氨氯地平微球制剂、其制备方法及应用
EP2497476A1 (en) Aripiprazole pamoate salt
JP2016515612A (ja) ドネペジルを含む非経口投与用の医薬組成物
EP2910242B1 (en) Durable analgetic sebacoyl dinalbuphine ester-plga controlled release formulation
WO2003004024A1 (en) Injectable sustained-release microspheres of huperzine a compounds
CN1762495B (zh) 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺
CA2990387A1 (en) Formulations for mitigating opioid overdose and methods of making and using the same
JP2026503608A (ja) 変形性関節症などの関節疾患の治療に使用するためのコルヒチンを含む関節内注射用剤形
EP1414419A1 (en) Pharmaceutical formulations comprising ketoconazole
CN102784111A (zh) 一种多巴胺受体激动剂类药物的缓释制剂
JP2024546571A (ja) 安定して放出可能な徐放性デリバリー製剤及びその製造方法
HK1107012B (en) Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
WO2006066509A1 (fr) Préparation microsphérique à libération prolongée injectable de dérivés de 3,3-diphénylpropylamine servant d'antagonistes du récepteur muscarinique
KR20240159619A (ko) 카리프라진 유리 염기 입자를 포함하는 주사용 디포우 제형
CN121401212A (zh) 一种前期无释放停滞期的卢美哌隆长效微球缓释制剂、制备方法
CN119212684A (zh) 新型组合物
TR2022013222A1 (tr) Naltrekson i̇çeren i̇n si̇tu jel oluşturan çözelti̇ler
HK1169940A (en) Aripiprazole pamoate salt
HK1186978B (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110118

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120828

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120903

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150907

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5081622

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term